MNOV Key Statistics, Chart & Performance
The current stock price of MNOV is 1.52 USD. In the past month the price increased by 0.66%. In the past year, price decreased by -22.45%.
MNOV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About MNOV
Company Profile
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. The company is headquartered in La Jolla, California and currently employs 13 full-time employees. The company went IPO on 2006-12-01. The firm's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Company Info
MEDICINOVA INC
4275 Executive Square, Suite 300
La Jolla CALIFORNIA 92037 US
CEO: Yuichi Iwaki
Employees: 13
Phone: 18583731500
MEDICINOVA INC / MNOV FAQ
What does MEDICINOVA INC do?
MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. The company is headquartered in La Jolla, California and currently employs 13 full-time employees. The company went IPO on 2006-12-01. The firm's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
What is the stock price of MEDICINOVA INC today?
The current stock price of MNOV is 1.52 USD. The price increased by 7.04% in the last trading session.
What is the dividend status of MEDICINOVA INC?
MNOV does not pay a dividend.
What is the ChartMill technical and fundamental rating of MNOV stock?
MNOV has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of MEDICINOVA INC (MNOV) based on its PE ratio?
MEDICINOVA INC (MNOV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.25).
What is the market capitalization of MNOV stock?
MEDICINOVA INC (MNOV) has a market capitalization of 74.56M USD. This makes MNOV a Micro Cap stock.
Who owns MEDICINOVA INC?
You can find the ownership structure of MEDICINOVA INC (MNOV) on the Ownership tab.
MNOV Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to MNOV. When comparing the yearly performance of all stocks, MNOV is a bad performer in the overall market: 69.37% of all stocks are doing better.
MNOV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MNOV. MNOV has a great financial health rating, but its profitability evaluates not so good.
MNOV Financial Highlights
Over the last trailing twelve months MNOV reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS decreased by -19.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.22% | ||
| ROE | -25.13% | ||
| Debt/Equity | 0 |
MNOV Forecast & Estimates
8 analysts have analysed MNOV and the average price target is 7.14 USD. This implies a price increase of 369.74% is expected in the next year compared to the current price of 1.52.